Gilead's Q2 Base Sales Rose 10%-But the Real Test Starts After Veklury Fades

Gilead's core business is still growing even after Veklury drops out

The most useful read of Gilead's Q2 report is not the headline EPS line. It is whether the company's core products are still moving. On that score, the answer is still yes: product sales excluding Veklury increased 10% year-over-year to $7.6 billion.

The earnings damage was real, but the demand signal was not. Gilead reported a diluted loss per share of $(8.45) and a non-GAAP diluted loss per share of $(6.75), with a $(9.08) per share acquired IPR&D and tax expense tied to recent deals. When a business truly loses customer traction, the first sign is usually weaker sales rather than strong base-business growth.

Biktarvy still matters, but the next catalyst is pipeline follow-through

Biktarvy remains the clearest proof point. Gilead said Biktarvy sales increased 7% year-over-year to $3.8 billion in Q2. A drug of that size does not keep growing unless doctors and patients are still choosing it.

If the market starts looking past the accounting hit, the next rerating catalyst is execution against management's pipeline roadmap. In Q1, management cited up to four potential launches and five Phase 3 updates anticipated in 2026. That is the bridge from a steady base business to a case for a higher valuation multiple.

HIV and oncology are driving Gilead's sales growth

One step beyond the headline number is the product mix. Gilead's recent growth has been broad enough to suggest a portfolio with more than one source of support.

HIV remains the largest engine

Gilead's own Q2 commentary highlighted HIV sales grew 12%, which supports the view that the segment is still performing well even as investors piece together brand-level detail from other materials.

That pattern is not new. In Q1, Gilead posted 8% growth in base business with HIV up 10%, and management specifically credited the successful launch of Yeztugo. That matters because it suggests part of the pipeline is already turning into commercial momentum.

Biktarvy's recent trajectory still looks intact

The broader Biktarvy sequence still looks constructive rather than distressed: Biktarvy sales increased 13% year-over-year to $13.4 billion for full year 2024, followed by Biktarvy sales increased 6% year-over-year to $3.7 billion in Q3 2025, and then Biktarvy sales increased 7% year-over-year to $3.8 billion in Q2 2026. Read together, those figures do not point to an abrupt loss of demand.

There is still a credibility watchpoint. The Q2 release also noted that the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). That does not overturn the broader growth story on its own, but it is a reminder to watch execution closely.

Bull case vs. bear case

The bullish view is straightforward: Biktarvy remains stable, HIV is still growing, and new launches are starting to add depth. The bearish view is that HIV can still be a narrow lane and that regional reporting issues deserve respect.

For now, the cleaner read is that the mix is improving, but investors should keep looking for evidence that oncology and other pillars continue supporting the base business rather than leaving growth entirely in HIV's hands.

Why the EPS loss may be distracting from product demand

One mistake in reading the quarter is confusing accounting damage with commercial weakness.

The market may be fixated on the wrong line item

Even the non-GAAP figure was still a loss of $6.75 a share, largely because of $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent Acquisitions. That is a powerful reminder that the income statement for this quarter says more about deal costs than about whether doctors are prescribing fewer Gilead drugs.

If product demand were weakening in a meaningful way, investors would usually expect to see pressure in sales growth or management commentary. So far, the base-business trend has moved the other direction.

Last year already showed how revenue mix can mislead

The clearest reality check comes from Q3 2025. In that quarter, product sales decreased 2%, yet total revenue still rose 3% because royalty, contract and other revenues increased by approximately $400 million. That is a good reminder that some of Gilead's reported revenue swings come from sources unrelated to core product demand.

Taken together, the recent record suggests a simple point: the EPS hit looks worse than the underlying commercial trend. The risk is that investors keep overreacting to deal noise while underweighting the fact that Gilead's base business has still been growing.

What keeps the bull case intact from here

The story is no longer about one noisy quarter. It is about whether core products keep selling and whether management can turn pipeline milestones into commercial follow-through.

What to watch

• Keep the bull case intact: continued growth in base-business sales and another quarter of steady HIV and Biktarvy performance.
• Make the case stronger: management delivers on up to four potential launches and five Phase 3 updates anticipated in 2026.
• Stay cautious: reported earnings remain distorted by acquired IPR&D and tax expenses.
• Question the optimism if: future quarters show weaker product growth after a period in which product sales decreased 2% while royalty, contract and other revenues increased by approximately $400 million.
• Watch execution closely: the update to Odefsey sales in Europe is a reminder that not all reporting has been straightforward.

For now, the better-supported read is modest rather than euphoric: Gilead's core business still looks healthy, but the next step in the stock story depends on follow-through, not just one quarter of strong base sales.